LTRN•benzinga•
EXCLUSIVE: Lantern Pharma Tells Benzinga ''The phase 1b/2 clinical trial plans to evaluate LP-184 in recurrent TNBC patients as both monotherapy and in combination with olaparib'
Summary
No summary available.
Original Article
Read the full article from the original source for complete details and context.
Read Full ArticleArticle published on May 5, 2025 by benzinga